Article Link: FDA Approves Genentech’s Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors South San Francisco, CA...
FDA Approves Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
Article Link: FDA Approves Seysara (sarecycline) for the Treatment of Moderate to Severe Acne Barcelona – 2nd October 2018 — ...
FDA Approves Nuzyra (omadacycline) for Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections
Article Link: FDA Approves Nuzyra (omadacycline) for Community-Acquired Bacterial Pneumonia and Acute Skin and Skin Structure Infections ...
FDA Approves Xyosted (testosterone enanthate) Injection for Testosterone Replacement Therapy in Adult Males
Article Link: FDA Approves Xyosted (testosterone enanthate) Injection for Testosterone Replacement Therapy in Adult Males EWING, N.J., Oc...
FDA Approves Kyprolis (carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple Myeloma
Article Link: FDA Approves Kyprolis (carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Cal...
FDA Approves Arikayce (amikacin liposome inhalation suspension) to treat Mycobacterium Avium Complex (MAC) Lung Disease
Article Link: FDA Approves Arikayce (amikacin liposome inhalation suspension) to treat Mycobacterium Avium Complex (MAC) Lung Disease Sep...
FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma
Article Link: FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma September 28, 2018 — The U.S. F...
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults
Article Link: FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults INDIANAPOLIS, Sept. 27, 2018 /...
FDA Approves Genentech's Xolair (omalizumab) Prefilled Syringe Formulation
Article Link: FDA Approves Genentech’s Xolair (omalizumab) Prefilled Syringe Formulation South San Francisco, CA — September ...
Eisai Announces FDA Approval of Fycompa in Pediatric Patients as Young as 4 Years Old for the Treatment of Partial-Onset Seizures
Article Link: Eisai Announces FDA Approval of Fycompa in Pediatric Patients as Young as 4 Years Old for the Treatment of Partial-Onset Seizures ...
